MktsMarkets

Passage Bio, Inc.
NASDAQ: PASGKey statistics
PASG News
Stories mentioning PASG from around the web — every one is an open thread, so give it a like or add your take.
Loading news…
Financial statements
As filed, straight from the 10-Q — up to 19 years of history, free, with every line item chartable.
| Line item | Q1 '26Mar 31 | Q4 '25Dec 31 | Q3 '25Sep 30 | Q2 '25Jun 30 | Q1 '25Mar 31 | Q4 '24Dec 31 | Q3 '24Sep 30 | Q2 '24Jun 30 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | ||||||||
| Cost of Goods Sold | ||||||||
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | ||||||||
| Research & Development | 4,093 | 5,418 | 4,307 | 5,814 | 7,737 | 9,558 | 8,656 | 10,430 |
| Sales General & Admin | ||||||||
| Total Operating Expenses | ||||||||
| Operating Income (Loss) | (8,247) | (13,848) | (8,655) | (10,334) | (16,459) | (14,270) | (20,702) | (17,378) |
| Interest Income | ||||||||
| Interest Expense | ||||||||
| Other Expense | 688.00 | 865.00 | 906.00 | 949.00 | 1,054 | 1,545 | 1,362 | 1,387 |
| Pretax Income | ||||||||
| Tax Provision | ||||||||
| Net Income (Loss) | (7,559) | (12,983) | (7,749) | (9,385) | (15,405) | (12,725) | (19,340) | (15,991) |
| Earnings Per Share (Basic) | (2.36) | (4.09) | (2.44) | (2.96) | (4.87) | (4.13) | (6.15) | (5.09) |
| Earnings Per Share (Diluted) | (2.36) | (4.09) | (2.44) | (2.96) | (4.87) | (4.13) | (6.15) | (5.09) |
| Weighted Average Shares Outstanding (Basic) | 3,206 | 3,173 | 3,179 | 3,169 | 3,164 | 3,079 | 3,147 | 3,143 |
| Weighted Average Shares Outstanding (Diluted) | 3,206 | 3,173 | 3,179 | 3,169 | 3,164 | 3,079 | 3,147 | 3,143 |
Scroll the table sideways for older periods — the line-item column and the period header stay put. Hover a row and use the chart handle to plot it over the full history.
About PASG
Passage Bio, Inc. (NASDAQ: PASG) is a stock listed on the Nasdaq Stock Market under the ticker symbol PASG. It last traded at $4.13 (Nov 18, 2026, 4:00 PM ET), down 2.0% on the day. That gives Passage Bio a market capitalisation of $13.5M.
Over the past 52 weeks PASG has traded between $3.29 and $20.00.
For the quarter ended Mar 31, 2026 it reported a net loss of $7.6M.
| Quarter ended | Revenue | Net income |
|---|---|---|
| Mar 31, 2026 | — | -$7.6M |
| Dec 31, 2025 | — | -$13.0M |
| Sep 30, 2025 | — | -$7.7M |
| Jun 30, 2025 | — | -$9.4M |
From Passage Bio’s quarterly (10-Q) filings, in US dollars.
Take a break — play a market game
Seven free games built around the markets. No download, no sign-up: they run right here in your browser.
Latest News
Market news from around the web — every story is an open thread, so give it a like or add your take.
Loading news…